Literature DB >> 11157679

Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin.

S S Pierangeli1, R G Espinola, X Liu, E N Harris.   

Abstract

Recent studies have shown that antiphospholipid (aPL) enhances expression of intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin on endothelial cells (ECs) and that these effects are correlated with increased adhesion of leukocytes to endothelium in cremaster muscle in vivo and with thrombosis in a mouse model. Activation of ECs by aPL may create a hypercoagulable state that precedes and contributes to thrombosis in patients with aPL syndrome (APS). This study proposed to examine whether this in vivo activation of ECs and enhanced thrombosis by aPL are mediated by ICAM-1, P-selectin, or VCAM-1. The dynamics of thrombus formation and the number of adhering leukocytes were studied in ICAM-1-deficient (ICAM-1(-/-)) mice or ICAM-1-/P-selectin-deficient (ICAM-1(-/-)/P-selectin(-/-)) mice treated with affinity-purified aPL antibodies (ap IgG-APS) or with control IgG and compared with wild-type mice treated in a similar fashion. In another set of experiments, the adhesion of leukocytes to cremaster muscle and the dynamics of thrombus formation were studied in CD1 mice treated with aPL or control IgG before and 30 minutes after intravenous infusion with 100 microg monoclonal antibody anti-VCAM-1. The results indicate that the enhanced adhesion of leukocytes to endothelium in wild-type mice was significantly reduced in ICAM-1(-/-) and completely abrogated in ICAM-1(-/-)/P-selectin(-/-) mice treated with ap IgG-APS compared with wild-type mice treated with ap IgG-APS (6.9+/-2.3, 0.4+/-0.4 versus 35+/-12, respectively). More importantly, this correlated with a significant reduction in thrombus size compared with wild-type mice treated with ap IgG-APS (895+/-259 microm(2), 859+/-243 microm(2) versus 3816+/-672 microm(2), respectively). Infusion of the mice with anti-VCAM-1 antibodies significantly reversed the enhanced adhesion of leukocytes (14.9+/-3 to 11.3+/-2.1) and thrombus size 3830+/-1008 microm(2) versus 876+/-548 microm(2)) in mice treated with ap IgG-APS. The data indicate that ICAM-1, P-selectin, and VCAM-1 expression are important in thrombotic complications by aPL antibodies and may provide novel targets for therapy in patients with APS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157679     DOI: 10.1161/01.res.88.2.245

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  35 in total

Review 1.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

2.  Large organized thrombus of the tricuspid valve: report of a case.

Authors:  Toshiharu Yamagishi; Kazuhiro Sakata
Journal:  Surg Today       Date:  2007-05-28       Impact factor: 2.549

3.  C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies.

Authors:  Al Carrera-Marín; Z Romay-Penabad; E Papalardo; E Reyes-Maldonado; E García-Latorre; G Vargas; T Shilagard; S Pierangeli
Journal:  Lupus       Date:  2012-08-29       Impact factor: 2.911

Review 4.  The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.

Authors:  Rohan Willis; E B Gonzalez; A R Brasier
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

5.  Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state.

Authors:  Jakub Swadzba; Teresa Iwaniec; Jacek Musial
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

Review 6.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 7.  Annexin A2: biology and relevance to the antiphospholipid syndrome.

Authors:  E Cockrell; R G Espinola; K R McCrae
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

8.  Pathophysiological mechanisms in antiphospholipid syndrome.

Authors:  Brock E Harper; Rohan Wills; Silvia S Pierangeli
Journal:  Int J Clin Rheumtol       Date:  2011-04-01

9.  Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.

Authors:  Zurina Romay-Penabad; Maria Guadalupe Montiel-Manzano; Tuya Shilagard; Elizabeth Papalardo; Gracie Vargas; Arun B Deora; Michael Wang; Andrew T Jacovina; Ethel Garcia-Latorre; Elba Reyes-Maldonado; Katherine A Hajjar; Silvia S Pierangeli
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

10.  Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Pojen P Chen; Keith R McCrae; Edwin G Bovill; Douglas J Taatjes
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.